1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
US7199142B2 · kind B2 · utility
12Cited by
3References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2003 |
| Grant date | Apr 3, 2007 |
| Priority date | — |
| Expiry date | Sep 22, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.